Tukman Grossman Capital Management Has Lowered Schlumberger LTD (SLB) Holding; Redhill Biopharma LTD. – American Depositary Share (RDHL) Sellers Increased By 12.95% Their Shorts

Redhill Biopharma LTD. – American Depositary Share (NASDAQ:RDHL) had an increase of 12.95% in short interest. RDHL’s SI was 345,300 shares in March as released by FINRA. Its up 12.95% from 305,700 shares previously. With 184,700 avg volume, 2 days are for Redhill Biopharma LTD. – American Depositary Share (NASDAQ:RDHL)’s short sellers to cover RDHL’s short positions. The SI to Redhill Biopharma LTD. – American Depositary Share’s float is 2.15%. The stock increased 2.30% or $0.13 during the last trading session, reaching $5.79. About 11,534 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 9.09% since March 19, 2017 and is downtrending. It has underperformed by 25.79% the S&P500.

Tukman Grossman Capital Management Inc decreased Schlumberger Ltd (SLB) stake by 49% reported in 2017Q3 SEC filing. Tukman Grossman Capital Management Inc sold 116,600 shares as Schlumberger Ltd (SLB)’s stock declined 11.04%. The Tukman Grossman Capital Management Inc holds 121,376 shares with $8.47 million value, down from 237,976 last quarter. Schlumberger Ltd now has $91.61B valuation. The stock increased 1.15% or $0.75 during the last trading session, reaching $66.1. About 9.39 million shares traded or 5.02% up from the average. Schlumberger Limited (NYSE:SLB) has declined 3.30% since March 19, 2017 and is downtrending. It has underperformed by 20.00% the S&P500.

Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma has $33 highest and $18 lowest target. $24.63’s average target is 325.39% above currents $5.79 stock price. RedHill Biopharma had 14 analyst reports since July 29, 2015 according to SRatingsIntel. Roth Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) on Monday, July 31 with “Buy” rating. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by TH Capital on Wednesday, July 29. The rating was initiated by Nomura on Tuesday, September 29 with “Buy”. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) has “Outperform” rating given on Friday, February 24 by FBR Capital. Roth Capital maintained RedHill Biopharma Ltd. (NASDAQ:RDHL) rating on Tuesday, November 14. Roth Capital has “Buy” rating and $20.0 target. As per Saturday, August 22, the company rating was upgraded by Zacks. As per Tuesday, August 25, the company rating was downgraded by TheStreet. On Thursday, June 15 the stock rating was maintained by FBR Capital with “Buy”. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by Northland Capital on Tuesday, September 29. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by H.C. Wainwright on Thursday, June 15.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $122.06 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

Analysts await Schlumberger Limited (NYSE:SLB) to report earnings on April, 20 before the open. They expect $0.40 earnings per share, up 60.00% or $0.15 from last year’s $0.25 per share. SLB’s profit will be $554.38 million for 41.31 P/E if the $0.40 EPS becomes a reality. After $0.48 actual earnings per share reported by Schlumberger Limited for the previous quarter, Wall Street now forecasts -16.67% negative EPS growth.

Among 39 analysts covering Schlumberger Limited. (NYSE:SLB), 32 have Buy rating, 1 Sell and 6 Hold. Therefore 82% are positive. Schlumberger Limited. had 141 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Schlumberger Limited (NYSE:SLB) earned “Buy” rating by Nomura on Monday, April 25. On Thursday, September 3 the stock rating was maintained by HSBC with “Buy”. The rating was upgraded by Bank of America on Monday, February 26 to “Buy”. As per Tuesday, April 26, the company rating was maintained by Barclays Capital. The firm has “Buy” rating by RBC Capital Markets given on Tuesday, January 16. Oppenheimer maintained it with “Outperform” rating and $92.0 target in Monday, January 25 report. The rating was initiated by DA Davidson on Friday, February 19 with “Buy”. The firm earned “Outperform” rating on Wednesday, April 26 by Cowen & Co. Societe Generale upgraded the shares of SLB in report on Tuesday, July 19 to “Buy” rating. The stock has “Buy” rating by Citigroup on Thursday, October 5.

Investors sentiment decreased to 0.66 in Q3 2017. Its down 0.22, from 0.88 in 2017Q2. It turned negative, as 69 investors sold SLB shares while 596 reduced holdings. 105 funds opened positions while 481 raised stakes. 1.20 billion shares or 11.55% more from 1.07 billion shares in 2017Q2 were reported. Ci Global holds 2,224 shares or 0% of its portfolio. Clifford Swan Invest Counsel Limited Liability Co, California-based fund reported 376,202 shares. Shelton Capital Mngmt stated it has 81,040 shares or 0.44% of all its holdings. Optimum Invest Advsr owns 19,924 shares. White Pine Ltd Liability Co has 0% invested in Schlumberger Limited (NYSE:SLB) for 5,318 shares. Green Square Limited Com reported 4,902 shares. Academy Capital Mgmt Tx stated it has 114,650 shares or 2.25% of all its holdings. Sol Capital Mgmt holds 0.11% or 5,726 shares. Aristotle Capital Mgmt Limited Com has 205,442 shares for 0.11% of their portfolio. Bessemer Group Inc Inc invested 0.14% in Schlumberger Limited (NYSE:SLB). Capwealth Advisors Ltd accumulated 40,934 shares. Reaves W H Co owns 35,847 shares. First Citizens Financial Bank & reported 5,851 shares or 0.05% of all its holdings. 4,703 were reported by Sequoia Finance Advsrs Ltd Company. Livingston Group Inc Asset Management (Operating As Southport Management) owns 0.11% invested in Schlumberger Limited (NYSE:SLB) for 3,855 shares.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: